InflaRx (IFRX) Total Liabilities (2016 - 2026)
InflaRx's (IFRX) quarterly Total Liabilities came in at $24.1 million in Q2 2026, up 29.78% year-over-year from $18.6 million in Q2 2025, and up 71.47% quarter-over-quarter from $14.0 million in Q1 2026.
Analysis
InflaRx (IFRX) Total Liabilities (2016 - 2026) Analysis & Trends
InflaRx has disclosed Total Liabilities across 11 years of filings, most recently posting $24.1 million for Q2 2026.
- In Q2 2026, Total Liabilities rose 29.78% year-over-year to $24.1 million; the TTM figure through Jun 2026 stood at $24.1 million (up 29.78% YoY), while the FY2025 annual figure was $15.4 million, down 1.1% from the prior year.
- Total Liabilities came in at $24.1 million for Q2 2026 at InflaRx, up from $14.0 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $24.1 million in Q2 2026 to a low of $8.3 million in Q1 2023.
- Average Total Liabilities over 5 years is $15.6 million, with a median of $15.0 million recorded in 2024.
- Year-over-year, Total Liabilities jumped 121.11% in 2022 and plunged 62.95% in 2023.
- Over 5 years, Total Liabilities stood at $14.3 million in 2022, then soared by 32.3% to $19.0 million in 2023, then decreased by 17.72% to $15.6 million in 2024, then climbed by 1.9% to $15.9 million in 2025, then jumped by 51.5% to $24.1 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $24.1 million in Q2 2026, $14.0 million in Q1 2026, and $15.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 384.62 Mn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | 24.09 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 24.09 Mn |
| Mar 31, 2026 | 14.05 Mn |
| Dec 31, 2025 | 15.90 Mn |
| Sep 30, 2025 | 23.14 Mn |
| Jun 30, 2025 | 18.56 Mn |
| Mar 31, 2025 | 17.39 Mn |
| Dec 31, 2024 | 15.60 Mn |
| Sep 30, 2024 | 15.82 Mn |
| Jun 30, 2024 | 11.72 Mn |
| Mar 31, 2024 | 13.40 Mn |
| Dec 31, 2023 | 18.97 Mn |
| Sep 30, 2023 | 12.51 Mn |
| Jun 30, 2023 | 9.06 Mn |
| Mar 31, 2023 | 8.30 Mn |
| Dec 31, 2022 | 14.33 Mn |
| Sep 30, 2022 | 11.77 Mn |
| Jun 30, 2022 | 13.34 Mn |
| Mar 31, 2022 | 22.40 Mn |
| Dec 31, 2021 | 22.72 Mn |
| Sep 30, 2021 | 16.68 Mn |